From Tissue-Agnostic to N-of-One Therapies:(R)Evolution of the Precision Paradigm

被引：101

作者：

Adashek, Jacob J. ^{[1
]}

Subbiah, Vivek ^{[2
]}

Kurzrock, Razelle ^{[3
,4
]}

机构：

[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33620 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA

[3] Univ Calif San Diego, Moores Canc Ctr, Ctr Personalized Canc Therapy, La Jolla, CA 92093 USA

[4] Univ Calif San Diego, Dept Med, Moores Canc Ctr, Div Hematol & Oncol, La Jolla, CA 92093 USA

来源：

TRENDS IN CANCER | 2021年 / 7卷 / 01期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; ABL TYROSINE KINASE; RETINOIC ACID; SOLID TUMORS; OPEN-LABEL; COMPARING CISPLATIN; 1ST-LINE THERAPY; TARGETED THERAPY;

D O I：

10.1016/j.trecan.2020.08.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Precision medicine has exploited next-generation sequencing (NGS) and gene/immune-targeted drug deployment to transform the outlook for several lethal cancers. For instance, there are now several FDA-approved medications that target the sequelae of aberrant genes in a tissue-agnostic approach: pembrolizumab [microsatellite instability and tumor mutational burden (TMB) >= 10 mutations/megabase (mut/Mb)] and larotrectinib/entrectinib (NTRK fusions). Molecular interrogation further reveals the disruptive reality that metastatic cancers are tremendously complex and individually distinct. Therefore, optimized treatment often requires drug combinations (rather than monotherapy) and N-of-one customization. Early studies of this approach suggest feasibility, safety, and efficacy. Real-world data/master registry trials may also provide massive, clinically relevant datasets that further fuel the (r)evolution in oncology.

引用

页码：15 / 28

页数：14

共 143 条

[1]

Adashek JJ, 2019, ANN ONCOL, V30

[2] Entrectinib: First Global Approval [J].

Al-Salama, Zaina T. ;

Keam, Susan J. .

DRUGS, 2019, 79 (13) :1477-1483

[3] TRANSLOCATION BREAKPOINT OF ACUTE PROMYELOCYTIC LEUKEMIA LIES WITHIN THE RETINOIC ACID RECEPTOR-ALPHA LOCUS [J].

ALCALAY, M ;

ZANGRILLI, D ;

PANDOLFI, PP ;

LONGO, L ;

MENCARELLI, A ;

GIACOMUCCI, A ;

ROCCHI, M ;

BIONDI, A ;

RAMBALDI, A ;

LOCOCO, F ;

DIVERIO, D ;

DONTI, E ;

GRIGNANI, F ;

PELICCI, PG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (05) :1977-1981

[4] AACR Project GENIE: Powering Precision Medicine through an International Consortium [J].

Andre, Fabrice ;

Arnedos, Monica ;

Baras, Alexander S. ;

Baselga, Jose ;

Bedard, Philippe L. ;

Berger, Michael F. ;

Bierkens, Mariska ;

Calvo, Fabien ;

Cerami, Ethan ;

Chakravarty, Debyani ;

Dang, Kristen K. ;

Davidson, Nancy E. ;

Del Vecchio, Fitz Catherine ;

Dogan, Semih ;

DuBois, Raymond N. ;

Ducar, Matthew D. ;

Futreal, P. Andrew ;

Gao Jianjiong ;

Garcia, Francisco ;

Gardos, Stu ;

Gocke, Christopher D. ;

Gross, Benjamin E. ;

Guinney, Justin ;

Heins, Zachary J. ;

Hintzen, Stephanie ;

Horlings, Hugo ;

Hudecek, Jan ;

Hyman, David M. ;

Kamel-Reid, Suzanne ;

Kandoth, Cyriac ;

Kinyua, Walter ;

Kumari, Priti ;

Kundra, Ritika ;

Ladanyi, Marc ;

Lefebvre, Celine ;

LeNoue-Newton, Michele L. ;

Lepisto, Eva M. ;

Levy, Mia A. ;

Lindeman, Neal, I ;

Lindsay, James ;

Liu, David ;

Lu Zhibin ;

MacConaill, Laura E. ;

Ian, Maurer ;

Maxwell, David S. ;

Meijer, Gerrit A. ;

Meric-Bernstam, Funda ;

Micheel, Christine M. ;

Miller, Clinton ;

Mills, Gordon .

CANCER DISCOVERY, 2017, 7 (08) :818-831

[5] Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET). [J].

Bartlett, Cynthia Huang ;

Mardekian, Jack ;

Yu-Kite, Michelle ;

Cotter, Matthew James ;

Kim, Sindy ;

Decembrino, Jaclyn ;

Snow, Tamara ;

Carson, Kenneth R. ;

Rockland, Jillian Motyl ;

Kraus, Albert L. ;

Wilner, Keith D. ;

Oharu, Norihiko ;

Schnell, Patrick ;

Lu, Dongrui ;

Tursi, Jennifer .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[6] Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence [J].

Bartlett, Victoria L. ;

Dhruva, Sanket S. ;

Shah, Nilay D. ;

Ryan, Patrick ;

Ross, Joseph S. .

JAMA NETWORK OPEN, 2019, 2 (10)

[7] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].

BEN-NERIAH, Y ;

DALEY, GQ ;

MESMASSON, AM ;

WITTE, ON ;

BALTIMORE, D .

SCIENCE, 1986, 233 (4760) :212-214

[8] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers [J].

Bergethon, Kristin ;

Shaw, Alice T. ;

Ou, Sai-Hong Ignatius ;

Katayama, Ryohei ;

Lovly, Christine M. ;

McDonald, Nerina T. ;

Massion, Pierre P. ;

Siwak-Tapp, Christina ;

Gonzalez, Adriana ;

Fang, Rong ;

Mark, Eugene J. ;

Batten, Julie M. ;

Chen, Haiquan ;

Wilner, Keith D. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Carbone, David P. ;

Ji, Hongbin ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari ;

Pao, William ;

Iafrate, A. John .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) :863-870

[9] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[10] Landscape of Microsatellite Instability Across 39 Cancer Types [J].

Bonneville, Russell ;

Krook, Melanie A. ;

Kautto, Esko A. ;

Miya, Jharna ;

Wing, Michele R. ;

Chen, Hui-Zi ;

Reeser, Julie W. ;

Yu, Lianbo ;

Roychowdhury, Sameek .

JCO PRECISION ONCOLOGY, 2017, 1 :1-15

← 1 2 3 4 5 6 7 8 9 10 →